ENA 003
Alternative Names: ENA-003Latest Information Update: 06 Oct 2021
At a glance
- Originator Enalare Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Respiration disorders
Most Recent Events
- 30 Sep 2021 ENA 003 is available for licensing in (excluding USA) as of 30 Sep 2021. https://enalare.com/home/pipeline/
- 30 Sep 2021 Phase-I clinical trials in Respiration disorders in USA (unspecified route), prior to September 2021 (Enalare Therapeutics pipeline, September 2021)
- 30 Sep 2021 Enalare Therapeutics plans to launch ENA 003 for Respiration disorders (Enalare Therapeutics pipeline, September 2021)